Skip to main content
SpringerLink
Log in

NEURO-ONCOLOGY

Glioma progression through synaptic activity

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Two new studies show that gliomas can manipulate normal elements of neuronal development and plasticity to create neuron–glia synapses, activation of which leads to glioma proliferation. Interventions that target the AMPA receptor could slow down tumour growth by altering this synaptic transmission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Venkatesh, H. S. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539–545 (2019).

    Article  CAS  Google Scholar 

  2. Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532–538 (2019).

    Article  CAS  Google Scholar 

  3. Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93–98 (2015).

    Article  CAS  Google Scholar 

  4. Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803–816 (2015).

    Article  CAS  Google Scholar 

  5. Venkatesh, H. S. et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549, 533–537 (2017).

    Article  Google Scholar 

  6. Lange, F. et al. AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS ONE 14, e0211644 (2019).

    Article  CAS  Google Scholar 

  7. Huberfeld, G. & Vecht, C. J. Seizures and gliomas - towards a single therapeutic approach. Nat. Rev. Neurol. 12, 204–216 (2016).

    Article  Google Scholar 

  8. Izumoto, S. et al. Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res. 38, 4361–4366 (2018).

    Article  CAS  Google Scholar 

  9. Grossman, S. A. et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J. Clin. Oncol. 27, 4155–4161 (2009).

    Article  CAS  Google Scholar 

  10. Iwamoto, F. M. et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 116, 1776–1782 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Neuro-Oncology, Dana Farber Cancer Institute, Boston, MA, USA

    Mary Jane Lim-Fat & Patrick Y. Wen

  2. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Patrick Y. Wen

  3. Harvard Medical School, Boston, MA, USA

    Patrick Y. Wen

Authors
  1. Mary Jane Lim-Fat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Y. Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Y. Wen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim-Fat, M.J., Wen, P.Y. Glioma progression through synaptic activity. Nat Rev Neurol 16, 6–7 (2020). https://doi.org/10.1038/s41582-019-0290-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0290-1

  • Springer Nature Limited

This article is cited by

Search

Navigation